TECX Tectonic Therapeutic, Inc.

Nasdaq tectonictx.com


$ 18.83 $ 2.17 (12.89 %)    

Thursday, 06-Nov-2025 19:01:26 EST
QQQ $ 613.36 $ -9.99 (-1.61 %)
DIA $ 470.23 $ -2.78 (-0.59 %)
SPY $ 671.96 $ -6.30 (-0.93 %)
TLT $ 89.61 $ 0.21 (0.23 %)
GLD $ 367.27 $ -1.11 (-0.3 %)
$ 18.99
$ 16.84
$ 18.00 x 350
$ 19.91 x 9
$ 16.59 - $ 20.66
$ 13.70 - $ 61.07
1,295,015
na
355.42M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-18-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-25-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of ...

Core News & Articles

Oppenheimer analyst Leland Gershell initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Outperform rating and an...

Core News & Articles

Truist Securities analyst Danielle Brill initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Buy rating and anno...

Core News & Articles

-SEC Filing

Core News & Articles

Raymond James analyst Michael Freeman reinstates Tectonic Therapeutic (NASDAQ:TECX) with a Outperform and announces $76 pric...

Core News & Articles

Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in pati...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION